COBALT VISION, INC.—AMD Vaccine
Cobalt Vision, Inc. (“Cobalt”) is a pre-clinical ophthalmic company that is developing a novel immunotherapy vaccine to slow or stop the progression of dry AMD, the largest cause of blindness for patients over the age of 55.  The company is a spin off of Ophthalmic Research Associates (“Ora”) located in Boston—the world’s leading independent vision care CRO and ophthalmic product development firm. Broad patent applications have been filed in the US and in Europe. Preliminary animal studies have been conducted with promising results. Next steps are to complete preclinical studies and file an IND in 2011.

The Company is seeking a Series A $10MM to complete a Phase 2a Proof of Concept study in Man.

Back To Top

ELENZA, INC.—Electronic Presbyopia-correcting Intraocular Lens
Elenza, Inc. (the new name for Ocular Optics), is developing the world’s first “AutoFocal” Presbyopia Correcting Intraocular Lens to compete in the multi-billion dollar IOL market for the correction of near, intermediate and distance vision. These electro-active lenses use a proprietary combination of chemistry, electricity, and integrated-circuitry to create smart optics, which will provide patients with the ability to see more naturally and clearly over a range of vision. The technology includes a non-mechanical dynamic aperture that automatically adjusts focusing power electronically, in milliseconds, to maintain constant in focus vision for various working needs and/or light environments. The lens is controlled by a power source only microns in diameter, which could sit on the head of a pin and an expected 20+ year battery life.

The Company is seeking a lead investor to close a $15.0 Million Series “B” round of financing, to be joined by existing investors including Delphi Ventures and The Carlyle Group

Back To Top

KLARITY™—Lubricant Eye Drop
Klarity was developed by Richard Lindstrom, MD for Refractive (LASIK/ PRK) and Postoperative Cataract, Corneal, Glaucoma and Vitreoretinal Surgery patients, as well as Contact Lens wearers after they remove their lenses. Klarity’s proprietary formulation contains special components that rehabilitate the stressed ocular surface by reducing corneal edema, scavenging free radicals, and creating a well lubricated enriched healing environment for the ocular surface, facilitating nutrition and regeneration of corneal tissue. This product is intended to serve an important and growing niche in the ophthalmic OTC market: patients that need a specialty high performance lubricating eye drop. The product line can also be formulated for certain Rx indications. Extensive product development, performance and focus group studies have been completed. The technology is both patented and the name can be trademarked.

Klarity is seeking a Licensing Agreement for the development and commercialization of this technology.

Back To Top

NEWCO (a spin-off from Rowiak)—Presbyopia Reversal Using a Femtosecond Laser
Rowiak, GmbH, a Hannover, Germany specialty laser company is spinning off a "NewCo," which is developing a patented presbyopia reversal technology. Presbyopia is the most common refractive error worldwide, affecting the reading ability of nearly everyone over the age of 45. The technology uses a femtosecond laser to create gliding planes in the crystalline lens. These gliding planes increase the lens elasticity, resulting in approximately 2-3 diopters of restored accommodation. The procedure takes only seconds and is completely non-invasive. There is no need for infection control or a sterile operating suite. A laboratory prototype has been developed and used on cadaver eyes and live animal studies with promising results. NewCo plans to begin human clinical trials in 2011. The Company has seven patents filed (three of them have already issued), and an experienced development team in place who are considered to be experts in femtosecond laser technology. Revenue is derived from laser sales plus sales of a high margin ìconsumable.

NewCo is seeking to raise an A-round financing of $7.5 million. Use of proceeds is for completion of a clinical prototype laser and to begin the clinical regulatory process.

Back To Top

NORWOOD EYE CARE—Epi-LASIK Refractive Surgery
Less invasive than conventional laser refractive surgery (LASIK) which uses a microkeratome or laser keratome to cut a flap in the stroma, Epi-LASIK represents a refractive solution with many advantages. With Epi-LASIK, a small hand-held instrument gently peels back the epithelium (rather than cutting the stroma layer, which never really heals/rejuvenates) to expose the ocular tissue to be ablated by the Excimer laser during refractive surgery. The epithelium re-grows and basically reverts to its pre-operative condition and function within a few weeks after surgery. Elimination of the stromal cut has many benefits including elimination of flap-related problems and significant reduction of LASIK-related dry eye and post-surgical haze.
Epi-LASIK was originally invented by Professor Ioannis Pallikaris, MD, PhD. Norwood Abbey Ltd. (Norwood Eye Care - Australia) acquired this technology from CIBA Vision several years ago and has spent considerable capital building a proprietary IP portfolio, developing an Epi-keratome device and commercializing this technology.

Norwood Abbey is seeking a strategic partner to continue the commercialization of Epi-LASIK.

Back To Top

NOVAVISION—Vision Restoration Therapy
NovaVision, Inc. (“NovaVision) currently located in Boca Raton, FL makes and provides FDA-cleared and CE marked medical devices to provide non-invasive Vision Restoration Therapy, or VRT. VRT is a patient-specific diagnostic and therapeutic platform that is clinically proven to restore lost vision resulting from stroke, traumatic brain injury, or other acquired brain injury. The Company was recently involved in pilot studies to determine the applicability of their technology in age-related macular degeneration and glaucoma. The Company has five issued and 10 applied for patents and operates two wholly owned subsidiaries: one in the US, the other in Germany. Approximately 3,000 patients have been treated to date with an average annual revenue in excess of $1 million for the past three years. The Company lost its venture funding and entered Chapter 7 bankruptcy on April 28, 2010. The US subsidiary is inactive while the German subsidiary continues to operate on a reduced basis. Assets of the Company include intellectual property, branding and an established patient base, computer equipment, office furnishings and VRT treatment algorithms.

The Magnum Group is assisting the Court appointed Trustee in the sale of NovaVision’s assets.

Back To Top

PIXELOPTICS, INC.—Electro Active Ophthalmic Lenses
PixelOptics, Inc. (“Pixel”) has developed intelligent ophthalmic lenses to compete in the multi billion dollar spectacle lens market for the correction of presbyopia (loss of near focus after the age of 40+). These electro-active lenses use a proprietary combination of chemistry, electricity, and other components to create smart optics, which will provide patients with the ability to see more naturally and clearly. They are “dynamic” (changing optical power) vs. lenses that are “static” (fixed optical power), which are found in current ophthalmic product offerings. These lenses automatically adjust focusing power electronically, in milliseconds, without any moving parts, to maintain constant in focus vision for various working needs and/or environments. In the future this technology may also be adapted for contact lenses and to provide an entrée to SuperVision (the ability to see better than 20/20).

In October 2008, Pixel launched atLast®, the World’s first Enhanced Multifocal Lens which provides 10X the amount of clear vision within five feet of the wearer's face and with 70% less image jump compared to a lined bifocal of equal power. In March 2009, the Company introduced BEHOLD™, the World’s first sub 1.0mm center thickness lens capable of passing the FDA's impact resistance requirements while being AR coated and without a cushion coat requirement. They continue to advance and develop products and plan to become the worlds premier composite lens company.

The Company has an experienced and accomplished management team and development partners, a robust product development strategy and an extensive patent portfolio. The technology does not require government reimbursement or FDA filing and approval. Primary funding to date (Series A, B & C) has been provided by The Carlyle Group, Delphi Ventures, Stark Investments, Panasonic Venture Group and Longitude Capital.

The Magnum Group provides various strategic and business development services for Pixel, from time to time, in connection with the commercialization of its products.

Back To Top

THE INNOVATION FACTORY—Medical Device Incubator
The Innovation Factory (“TIF”) is one of the premier medical device incubators in the US, responsible for a number of successfully launched medical device companies, both ophthalmic and other medical specialties. TIF’s business model involves identifying and acquiring promising device technologies, financing those technologies through TIF’s venture capital affiliates, incubating those technologies within TIF’s organization of managerial, clinical and technical experts and ultimately building those technologies into independent operating companies for future commercialization. TIF is affiliated with a venture capital fund, Accuitive Medical Ventures. Ophthalmic companies successfully developed by TIF include AcuFocus, AqueSys and NeoVista.

The Magnum Group is a retained business development advisor to TIF in connection with the identification and acquisition of promising early-stage ophthalmic device technologies.

Back To Top

WOUND HEALING OF OKLAHOMA, INC.—Glaucoma Filtration Device
Wound Healing of Oklahoma (“WHO”) has developed an ophthalmic medical device for the treatment and control of glaucoma called CellPlant™. The CellPlant device was in development for over three years before the initiation of both animal and human clinical studies. It’s unique form and construction material has effectively eliminated many of the complications and drawbacks of conventional pharmaceutical and surgical glaucoma approaches and devices. CellPlant is permanent, easy to implant and has virtually no complications. Because of its unique material this device should have a lower production cost than any other glaucoma device on the market or known to be in development. The device has a total of eleven (11) awarded patents and four pending patents.

The CellPlant device has been successfully implanted in human subjects, (in two separate trials) with various types of severe glaucoma. Patients were followed for 24 months in the first study in China; a second human trial was initiated in 2005 in South Africa and aborted due to the exit of the Sponsoring Company from the ophthalmic market.

WHO is seeking a Strategic Partner to commercialize the CellPlant product in the form of a worldwide licensing or sales agreement. Specific terms of such an agreement are negotiable.